ReviewCurrent atherosclerosis reports2026
Single-cell Technologies in Atherosclerosis: Uncovering Cellular Heterogeneity, Mechanisms, and Therapeutic Opportunities.
Review in Current atherosclerosis reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review highlights recent advances in single-cell analysis technologies and their application in clarifying the cellular and molecular complexity of atherosclerosis, redefining our understanding of vascular biology and immune cell functioning within the atherosclerotic plaque. RECENT
findingsSingle-cell RNA sequencing (scRNA-seq), single-cell ATAC-seq, and spatial transcriptomics have revealed an unforeseen diversity of immune and vascular cell states in human and experimental prototypes of atherosclerosis. These techniques have led to the finding of novel macrophage and smooth muscle cell (SMC) phenotypes, distinct endothelial dysfunction signatures, and oligoclonal T cell populations. By integrating transcriptomic, epigenomic, proteomic, and spatial data, researchers have clarified key mechanisms of disease progression and identified cell-specific molecular pathways responsive to targeted therapy. Single-cell methods are changing our understanding of atherosclerosis by determining the heterogeneity, plasticity, and functional states of plaque-resident cells. These understandings contribute for the development of novel biomarkers, precision diagnostics, and targeted immunomodulatory strategies, with the ultimate goal of improving risk stratification and personalized treatment in atherosclerotic cardiovascular disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.